CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Clinical trials for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) explained in plain language.
Never miss a new study
Get alerted when new CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) trials appear
Sign up with your email to follow new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Armored immune cells take on tough blood cancers in early trial
Disease control OngoingThis early-phase study tests a new type of immune cell therapy for people with certain blood cancers (like CLL) that have not responded to standard treatments. The cells are taken from the patient, modified with an 'armor' to make them stronger, and then given back. The main goal…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
Triple-Drug attack shows promise against untreated CLL
Disease control OngoingThis study tested a combination of three drugs (acalabrutinib, venetoclax, and obinutuzumab) as a first treatment for people with chronic lymphocytic leukemia (CLL) who had not received prior therapy. The goal was to see if the combo could clear cancer cells from the bone marrow.…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Promising combo aims to control CLL without chemo
Disease control OngoingThis study is testing a combination of two drugs, venetoclax and obinutuzumab, in 100 people with chronic lymphocytic leukemia (CLL) who have not had treatment before. The goal is to see how well the combo controls the cancer and improves survival. Participants must be fit enough…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
CLL breakthrough: could some patients finally stop daily pills?
Disease control OngoingThis study looks at whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have very low levels of cancer cells (called MRD-negative) after taking venetoclax can stop the drug and stay healthy for at least a year. About 81 adults who are al…
Matched conditions: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:46 UTC